Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polypeptide targeting egfr to inhibit egf to promote tumor cell proliferation

A cell proliferation and targeting technology, applied in the field of biomedicine, can solve the problems of high production cost of monoclonal antibodies, many adverse reactions of patients, strong toxic and side effects of small molecule inhibitors, etc., and achieves easy to achieve large-scale production and short peptide sequences. , the effect of low production cost

Active Publication Date: 2021-08-03
JIANGSU UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, tumor molecular targeting drugs targeting EGFR are mainly divided into two categories according to their properties: one is monoclonal antibodies, and currently on the market in my country are cetuximab, panitumumab, and nimotuzumab anti-antibody, etc., but monoclonal antibodies have the problem of high production costs; the other is small molecule inhibitors, such as gefitinib, erlotinib and lapafenib, which have been on the market, but the toxicity of small molecule inhibitors Strong side effects, patients with more adverse reactions after medication

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide targeting egfr to inhibit egf to promote tumor cell proliferation
  • Polypeptide targeting egfr to inhibit egf to promote tumor cell proliferation
  • Polypeptide targeting egfr to inhibit egf to promote tumor cell proliferation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1: Construction of pET-30a / EGFR-ECD expression vector

[0024] The DNA sequence encoding the 25th to 645th amino acids (aa25-645) of the EGFR extracellular domain (EGFR-ECD, EGFR extracellular domain) fragment was extracted from Genebank (https: / / www.ncbi.nlm.nih.gov, login No.: CCDS5514.1), as shown in SEQ.ID.NO.2, and design PCR primers based on it:

[0025] Forward primer (SEQ.ID.NO.3): 5'-GCTGATATC GGATCC ATGCTGGAGGAAAAGAAAGT-3'

[0026] and reverse primer (SEQ.ID.NO.4): 5'-ACGGAGCTC GAATTC TCAGGACGGGATCTTAGG-3', the underlined parts are the restriction sites BamHI and EcoRI at both ends respectively. The PCR product of the target gene EGFR-ECD and the vector pET-30a (Novagen, #69909-3) were digested with BamHI and EcoRI at 37°C for 1 h, then ligated with T4 DNA ligase at 16°C for 12 h. Transform the ligation product into DH5α competent cells (full gold, CD201), wait for a single colony to grow on the kanamycin (50 µg / mL) resistant LB plate, pick a ...

Embodiment 2

[0028] Example 2: Induced expression and refolding purification of EGFR-ECD

[0029] Induced expression of EGFR-ECD: Transform the successfully constructed recombinant plasmid pET-30a / EGFR-ECD into the host strain BL21(DE3) (full gold, CD601), use the kanamycin resistance plate to screen recombinants, and pick single The colonies were cultured in LB liquid medium containing kanamycin for 10 h. The culture was inoculated in LB liquid medium at a volume ratio of 1:100, and cultured to OD at 37°C with vigorous shaking 600 =0.5-0.6, add 0.1 M IPTG to make the final concentration 0.5 mM, and induce at 25°C for 4 h.

[0030] Verification of the expression of the target protein: Centrifuge the bacterial solution obtained from the above induced expression at 5000 rpm for 10 min, remove the supernatant, and resuspend the bacteria in the lysate (50 mM Tris -HCl pH7.5, 500 mM NaCl, 10% glycerol, 1% TritonX-100, 1 mM protease inhibitor PMSF, 1 mg / mL lysozyme), placed on ice and sonicate...

Embodiment 3

[0034] Example 3: Phage display panning for biologically active peptides specifically binding to EGFR

[0035] Immobilization of target molecules: Add 100 µL of target molecule EGFR-ECD solution with a concentration of 100 µg / mL (the base solution is 0.1 MpH7.4 TBS) into a 96-well plate, place on a shaker and vibrate slightly, and place in a humidified container Incubate overnight at 4°C. The target molecule solution was removed and washed 6 times with TBS-T (50 mM Tris-HCl pH7.5, 150 mM NaCl, 0.1% [v / v] Tween-20). Finally, block with blocking solution (0.1 M NaHCO3 pH8.6, 5 mg / mL BSA, 0.02% NaN3) for 1 h.

[0036] Binding of phage random peptide library to target molecules: remove the blocking solution and wash 10 times with TBS-T (containing 0.1% [v / v] Tween-20). Phage library or amplified phage (purchased from NEB (Beijing) Co., Ltd., E8111, Ph.D.-12 Phage Display Peptide Library) diluted with TBS-T (containing 0.1% [v / v] Tween-20) , the titer of phage was 10 9 -10 11 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a polypeptide that targets EGFR and inhibits EGF and promotes tumor cell proliferation, and belongs to the technical field of biomedicine. The invention uses epidermal cell growth factor EGF as a target molecule, and through phage display technology panning, EGF is used as an effective component specificity The phage bound to the target molecule is eluted to obtain the biologically active polypeptide TUZG20; it is confirmed by the present invention that the biologically active polypeptide TUZG20 significantly inhibits the gastric cancer cell proliferation process caused by EGF; the polypeptide sequence of the present invention is short, easy to synthesize and realize large-scale production, It can inhibit the cancer-promoting effect of EGF, and has the potential for subsequent development as an anti-cancer drug, and has important application value in the research and development of anti-cancer drugs.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to a polypeptide targeting EGFR and inhibiting EGF to promote tumor cell proliferation. Background technique [0002] EGFR (Epidermal Growth Factor Receptor) is a member of the epidermal growth factor receptor family, widely distributed on the surface of mammalian epithelial cells, fibroblasts, glial cells, keratinocytes and other cells. The EGFR signaling pathway plays an important role in physiological processes such as cell growth, proliferation and differentiation. Epidermal Growth Factor (EGF, Epidermal Growth Factor) is an active cytokine in the human body, which stimulates the growth, proliferation and differentiation of cells by binding to its receptor EGFR. EGF is a protein with a molecular weight of 6 kD. It has 53 amino acid residues and three intramolecular disulfide bonds. It has an isoelectric point of 4.6 and is stable to heat. It is one of the most stable proteins...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/08A61K38/10A61P35/00
CPCA61K38/00A61P35/00C07K7/08
Inventor 屠志刚李濡妍刘晗青卢子文徐涵任德万
Owner JIANGSU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com